Mizuho calls it “grossly misleading” to suggest that challenges to the intellectual property related to FMC‘s flagship insecticide product is “anything new” and adds that FMC has been “successfully defending diamides’ IP for a decade (plus).” The decline in FMC shares following Blue Orca’s publication of a short report targeting FMC is a “material overreaction,” added the analyst, who keeps a Buy rating and $122 price target on FMC shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on FMC:
- FMC calls Blue Orca’s short report ‘misleading,’ shows inaccuracies
- Blue Orca says short FMC following ‘recent string of stunning legal defeats’
- Lowe’s upgraded, General Mills downgraded: Wall Street’s top analyst calls
- FMC Corporation downgraded to Neutral from Buy at UBS
- FMC receives Brazilian registration for fluindapyr SDHI fungicide